期刊文献+

VPA联合As_2O_3对NB_4细胞VEGF及Survivin表达的影响 被引量:1

EFFECTS OFVPACOMBINEDARSENIC TRIOXIDE ON THE EXPRESSION OFVEGFAND SURVIVIN IN NB4CELLLINES
下载PDF
导出
摘要 目的:探讨丙戊酸钠(VPA)联合三氧化二砷(As2O3)对NB4细胞株血管内皮生长因子(VEGF)、凋亡抑制蛋白Survivin表达的影响。方法:NB4细胞分为对照组、As2O3组及As2O3联合VPA组,RT-PCR方法检测NB4细胞VEGF、Survivin mRNA的表达。结果:As2O30.1μmol/L组NB4细胞VEGF mRNA的表达明显高于对照组、Survivin mRNA的表达明显低于对照组(P<0.05);与As2O30.1μmol/L组比较,As2O30.1μmol/L+VPA 1.0mmol/L组NB4细胞VEGF mRNA、Survivin mRNA的表达均明显降低(P<0.05)。结论:VPA联合小剂量As2O3可以降低单独应用As2O3导致的NB4细胞VEGF表达的升高、并进一步降低Survivin的表达,As2O3联合VPA可降低As2O3治疗急性早幼粒细胞白血病时的不良反应。 Objective:To investigate the effects of valproic acid (VPA) combined arsenic trioxide (As2O3) on expression of vascular endothelial growth factor (VEGF) and Survivin in NB4 cells lines.Methods:NB4 cells were divided into control group, As2O3 group and VPA+As2O3 group. RT-PCR was used to detect the VEGF and Survivin mRNA expression in NB4 cells.Results:VEGF mRNA expression in NB4 cells ofAs2O3 0.1 μmol/L group was obviously higher than that of control group,while Survivin mRNA expression was obviously lower(P〈 0.05).Compared with As2O3 0.1μmol/L group,the VEGF and Survivin mRNA expression in NB4 cells ofAs203 0.1μmol/L+VPA 1.0mmol/L group were all obviously decreased (P〈 0.05). Conclusions: VPA combined small dose As203 can reduce increasing of VEGF expression in NB4 cells induced by application of As2O3 alone, and can fuaher reduce Survivin expression. So, VPA combined As2O3 can reduce the side effects of As2O3 for treating acute promyelocytic leukemia.
出处 《承德医学院学报》 2013年第3期185-187,共3页 Journal of Chengde Medical University
基金 河北省自然科学基金项目(C2008000660)
关键词 三氧化二砷 丙戊酸钠 血管内皮生长因子 Survivin NB4细胞株 Arsenic trioxide Valproic acid VEGF Survivin NB4 cell lines
  • 相关文献

参考文献8

  • 1Park JH, Qiao B, Panageas KS, et al. Early death rate in acute promyelocytic leukemia remains high despite all-lrans retinoic acid[J]. Blood, 2011, 118(5):1248-1254.
  • 2Yang M, Liu Y, Lu S, Wang Z, et al. Analysis of the expression levels of survivin and VEGF in patients with acute lymphoblastic leukemia[J]. Exp Ther Med, 2013, 5(1):305-307.
  • 3Wang H, Hao L, Wang X, et al. Retrospective study of arsenic Irioxide for childhood acute promyelocytic leukemia in China: a single-center experience[J]. Int J Hematol, 2010, 91(5): 820-825.
  • 4Roboz GJ, Dias S, I_am G,et al. Arsenic Irioxide induces dose- and time-dependent apoptosis of endothelium and may exert an antileukemic effect via inhibition ofangiogenesis[J]. Blood, 2000, 96(4): 1525-1530.
  • 5De Junge H J, Weidenaar AC, Ter Elst A, et al. Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia[J]. Clin Cancer Res, 2008, 14(3):924-930.
  • 6Ryan BM, O'Donovan N, Duffy MJ. Survivin: a new target for anticancer therapy[J]. Cancer Treat Rev, 2009, 35(7):553-562.
  • 7Delvaeye M, De Vriese A, Zwerts F, et al. Role of the 2 zebrafish survivingenes in vaaxlo-angiogenesis, neurogenesis, cardiogenesis and hematopoiesis[J]. BMC Dev Biol, 2009, 9:25.
  • 8Demanne CF, Bonjean K, Servotte S, et al. Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling[J]. Oncogene, 2002, 21(3):427-436.

同被引文献14

  • 1谭竞,刘霆,朱焕玲,孟文彤,余江.三氧化二砷对多发性骨髓瘤骨髓基质细胞增殖及分泌细胞因子的影响[J].中国实验血液学杂志,2006,14(2):258-261. 被引量:6
  • 2Christoph Rollig,Thomas Illmer.The efficacy of arsenic trioxide for the treatment of relapsed and refractory multiple myeloma:a systematic review.Cancer Treat Rev,2009;35(4):425-430.
  • 3Zohreh Sanaat,Mahtab Rezazadeh,Jalial Vaez Gharamaleki,et al.Arsenic Trioxide in Patients with Refractory Multiple Myeloma:A Prospective,Phase Ⅱ,Single-Arm Study.Acta Medica Iranica,2011;49(8):503-508.
  • 4Guifang Ouyang,Maofang Lin.Arsenic trioxide potentiates the effect of bortezomib on the proliferation and apoptosis of multiple myeloma cell line KM3.Chinese-German Journal of Clinical Oncology,2010;9(3):175-179.
  • 5Shannon M.Matulis,Alejo A.Morales,Lucy Yehiayan,et al.Alterations in Glutathione Levels and Apoptotic Regulators Are Associated with Acquision of Arsenic Trioxide Resistance in Multiple Myeloma.Plos one,2012;12(7):1-14.
  • 6Carew JS,Giles FJ,Nawrocki ST.Histone deacetylase inhibitors:Mechanisms of cell death and promise in combination cancer therapy.Cancer Lett,2008;3(269):7-17.
  • 7Siegel DS,Dimopoulos MA,Yoon SS,et al.VANTAGE 095:final vesults from a global,single-arm,phase 26 trial of vorinostat in combination with bortezomib in salvaye multiple myeloma patients.Maematologica,2012;97(1):119.
  • 8Dimopoulos M,Siegel DS,Lonial S,et al.Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma(VANTAGE 088):a multicentre,randomised,double-blind study.Lancet Oncol,2013;4(11):1129-1140.
  • 9侯芸华,张永利,宋振岚,麦玉洁,李宁宁.三氧化二砷、沙利度胺、M2方案联合治疗复发、难治性多发性骨髓瘤疗效观察[J].白血病.淋巴瘤,2010,19(7):434-435. 被引量:1
  • 10周秀杰,周郁鸿.三氧化二砷(As_2O_3)治疗多发性骨髓瘤机理的研究进展[J].中医学报,2010,25(6):1052-1054. 被引量:3

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部